Advertisement

Tumor Biology

, Volume 35, Issue 6, pp 6113–6118 | Cite as

p16 CDKN2A SNP rs11515 was not associated with head and neck carcinoma

  • Ugo Borges Pinheiro
  • Carlos Alberto de Carvalho Fraga
  • Danilo Cangussu Mendes
  • Luciano Marques-Silva
  • Lucyana Conceição Farias
  • Marcela Gonçalves de Souza
  • Mariana Batista Soares
  • Kimberly Marie Jones
  • Sérgio Henrique Souza Santos
  • Alfredo Maurício Batista de Paula
  • Gustavo Velásquez-Meléndez
  • André Luiz Guimarães
Research Article

Abstract

Head and neck squamous cell carcinoma (HNSCC) is considered a serious public health problem in many countries. Recently, genetic variations have been considered as important factors to cancer susceptibility and prognosis. More specifically, genetic polymorphisms have been associated with the development and prognosis of HNSCC. The purpose of the current study was to investigate an association among p16 CDKN2A gene polymorphism at rs11515, age, and HNSCC aggressiveness. PCR–RFLP analysis was used to investigate the p16 CDKN2A gene in 96 patients with HNSCC and in 100 individuals without HNSCC. A case group was categorized by age in younger (<60 years) and older (≥60 years) patients. Differences between the case and control groups were determined using Fisher and chi-squared tests. Time of survival was calculated from the date of diagnosis to the date of last follow-up visit or to the date of death using the Kaplan–Meier estimator and comparing this to the log-rank test. Statistical significance was set at p < 0.05. In the present study, no association was established between HNSCC and rs11515 polymorphism, as indicated in a previous study. We found that HNSCC individuals with large-sized tumors and with metastatic disease presented worse overall survival, consistent with fundamental concepts that establish the effects of tumor size and lymph node metastasis to HNSCC outcomes. This study identified that there is no difference in the distribution of rs11515 between the control and HNSCC groups. In addition, no differences between rs11515 genotypes and clinicopathological parameters were observed.

Keywords

Suppressor gene CDKN2A Polymorphism Cancer Genetic 

Notes

Acknowledgments

This study was supported by grants from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), and Fundação de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG). Dr. Guimarães, Dr. Santos, and Dr. de Paula are research fellows of CNPq.

Conflicts of interests

None.

Ethical statement

All authors abide by the Association for Medical Ethics’ ethical rules of disclosure.

References

  1. 1.
    Argiris A, Eng C. Epidemiology, staging, and screening of head and neck cancer. Cancer Treat Res. 2003;114:15–60.CrossRefPubMedGoogle Scholar
  2. 2.
    Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371(9625):1695–709.CrossRefPubMedGoogle Scholar
  3. 3.
    Gritz ER, Carr CR, Rapkin DA, Chang C, Beumer J, Ward PH. A smoking cessation intervention for head and neck cancer patients: trial design, patient accrual, and characteristics. Cancer Epidemiol Biomarkers Prev. 1991;1(1):67–73.PubMedGoogle Scholar
  4. 4.
    Dobrossy L. Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev. 2005;24(1):9–17.CrossRefPubMedGoogle Scholar
  5. 5.
    Farias LC, Fraga CA, De Oliveira MV, Silva TF, Marques-Silva L, Moreira PR, et al. Effect of age on the association between p16CDKN2A methylation and DNMT3B polymorphism in head and neck carcinoma and patient survival. Int J Oncol. 2010;37(1):167–76.PubMedGoogle Scholar
  6. 6.
    De Paula AM, Souza LR, Farias LC, Correa GT, Fraga CA, Eleuterio NB, et al. Analysis of 724 cases of primary head and neck squamous cell carcinoma (HNSCC) with a focus on young patients and p53 immunolocalization. Oral Oncol. 2009;45(9):777–82.CrossRefPubMedGoogle Scholar
  7. 7.
    Soudry E, Preis M, Hod R, Hamzany Y, Hadar T, Bahar G, et al. Squamous cell carcinoma of the oral tongue in patients younger than 30 years: clinicopathologic features and outcome. Clin Otolaryngol. 2010;35(4):307–12. PubMed PMID: 20738340.CrossRefPubMedGoogle Scholar
  8. 8.
    Llewellyn CD, Johnson NW, Warnakulasuriya KA. Risk factors for squamous cell carcinoma of the oral cavity in young people—a comprehensive literature review. Oral Oncol. 2001;37(5):401–18.CrossRefPubMedGoogle Scholar
  9. 9.
    Llewellyn CD, Johnson NW, Warnakulasuriya S. Factors associated with delay in presentation among younger patients with oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97(6):707–13.CrossRefPubMedGoogle Scholar
  10. 10.
    Llewellyn CD, Linklater K, Bell J, Johnson NW, Warnakulasuriya KA. Squamous cell carcinoma of the oral cavity in patients aged 45 years and under: a descriptive analysis of 116 cases diagnosed in the South East of England from 1990 to 1997. Oral Oncol. 2003;39(2):106–14.CrossRefPubMedGoogle Scholar
  11. 11.
    Pytynia KB, Grant JR, Etzel CJ, Roberts D, Wei Q, Sturgis EM. Matched analysis of survival in patients with squamous cell carcinoma of the head and neck diagnosed before and after 40 years of age. Arch Otolaryngol Head Neck Surg. 2004;130(7):869–73. PubMed PMID: 15262765.CrossRefPubMedGoogle Scholar
  12. 12.
    Garavello W, Spreafico R, Gaini RM. Oral tongue cancer in young patients: a matched analysis. Oral Oncol. 2007;43(9):894–7. PubMed PMID: 17307026.CrossRefPubMedGoogle Scholar
  13. 13.
    Alves LR, Fraga CA, Oliveira MV, Sousa AA, Jorge AS, Marques-Silva L, et al. High HIF-1alpha expression genotypes increase odds ratio of oral cancer. Head Neck Oncol. 2012;4(5):87. PubMed PMID: 23296286.Google Scholar
  14. 14.
    Wang JR, Gramling SJ, Goldstein DP, Cheng D, Chen D, Azad AK, et al. Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk. Carcinogenesis. 2013. doi: 10.1093/carcin/bgt008. PubMed PMID: 23322154.Google Scholar
  15. 15.
    Fraga CA, Sousa AA, Correa GT, Jorge AS, Jesus SF, Jones KM, et al. High hypoxia-inducible factor-1alpha expression genotype associated with Eastern Cooperative Oncology Group performance in head and neck squamous cell carcinoma. Head Neck Oncol. 2012;4(4):77. PubMed PMID: 23250149.Google Scholar
  16. 16.
    Correa GT, Bandeira GA, Cavalcanti BG, Santos FB, Neto JF, Guimaraes AL, et al. Analysis of ECOG performance status in head and neck squamous cell carcinoma patients: association with sociodemographical and clinical factors, and overall survival. Support Care Cancer. 2012. PubMed PMID: 22314971. Epub 2012/02/09. Eng.Google Scholar
  17. 17.
    Dutra RL, de Carvalho MB, Dos Santos M, Mercante AM, Gazito D, de Cicco R, et al. FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx. PLoS One. 2012;7(11):e50747. PubMed PMID: 23226373.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Lee JM, Yang PW, Yang SY, Chuang TH, Tung EC, Chen JS, et al. Genetic variants in DNA repair predicts the survival of patients with esophageal cancer. Ann Surg. 2011;253(5):918–27. PubMed PMID: 21490450.CrossRefPubMedGoogle Scholar
  19. 19.
    Sauroja I, Smeds J, Vlaykova T, Kumar R, Talve L, Hahka-Kemppinen M, et al. Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer. 2000;28(4):404–14. PubMed PMID: 10862049.CrossRefPubMedGoogle Scholar
  20. 20.
    Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, et al. CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst. 1999;91(5):446–52. PubMed PMID: 10070944.CrossRefPubMedGoogle Scholar
  21. 21.
    Liggett Jr WH, Sewell DA, Rocco J, Ahrendt SA, Koch W, Sidransky D. p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res. 1996;56(18):4119–23. PubMed PMID: 8797577.PubMedGoogle Scholar
  22. 22.
    Thakur N, Hussain S, Nasare V, Das BC, Basir SF, Bharadwaj M. Association analysis of p16 (CDKN2A) and RB1 polymorphisms with susceptibility to cervical cancer in Indian population. Mol Biol Rep. 2012;39(1):407–14. PubMed PMID: 21567202.CrossRefPubMedGoogle Scholar
  23. 23.
    Zheng Y, Shen H, Sturgis EM, Wang LE, Shete S, Spitz MR, et al. Haplotypes of two variants in p16 (CDKN2/MTS-1/INK4a) exon 3 and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Epidemiol Biomarkers Prev. 2002;11(7):640–5. PubMed PMID: 12101111.PubMedGoogle Scholar
  24. 24.
    Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci U S A. 2003;100(1):177–82.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Sobin LH. TNM: evolution and relation to other prognostic factors. Semin Surg Oncol. 2003;21(1):3–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Sobin LH, Fleming ID. TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80(9):1803–4.CrossRefPubMedGoogle Scholar
  27. 27.
    Correa GT, Bandeira GA, Cavalcanti BG, de Carvalho Fraga CA, Dos Santos EP, Silva TF, et al. Association of -308 TNF-alpha promoter polymorphism with clinical aggressiveness in patients with head and neck squamous cell carcinoma. Oral Oncol. 2011;47(9):888–94.CrossRefPubMedGoogle Scholar
  28. 28.
    Fonseca-Silva T, Farias LC, Cardoso CM, Souza LR, Carvalho Fraga CA, Oliveira MV, et al. Analysis of p16(CDKN2A) methylation and HPV-16 infection in oral mucosal dysplasia. Pathobiology. 2012;79(2):94–100. PubMed PMID: 22285991.CrossRefPubMedGoogle Scholar
  29. 29.
    Fonseca-Silva T, Oliveira MV, Fraga CA, Farias LC, Gomes EP, Barros LO, et al. DNMT3B (C46359T) polymorphisms and immunoexpression of DNMT3b and DNMT1 proteins in oral lichen planus. Pathobiology. 2012;79(1):18–23. PubMed PMID: 22236544.CrossRefPubMedGoogle Scholar
  30. 30.
    Fraga CA, de Oliveira MV, de Oliveira ES, Barros LO, Santos FB, Gomez RS, et al. A high HIF-1alpha expression genotype is associated with poor prognosis of upper aerodigestive tract carcinoma patients. Oral Oncol. 2012;48(2):130–5. PubMed PMID: 21945343.CrossRefPubMedGoogle Scholar
  31. 31.
    Guimaraes AL, Correia-Silva JF, Diniz MG, Xavier GM, Horta MC, Gomez RS. Investigation of functional gene polymorphisms: IL-1B, IL-6 and TNFA in benign migratory glossitis in Brazilian individuals. J Oral Pathol Med. 2007;36(9):533–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Guimaraes AL, De Sa AR, Victoria JM, De FC-S, Gomez MV, Gomez RS. Interleukin-1beta and serotonin transporter gene polymorphisms in burning mouth syndrome patients. J Pain. 2006;7(9):654–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Tsygankov D, Liu Y, Sanoff HK, Sharpless NE, Elston TC. A quantitative model for age-dependent expression of the p16INK4a tumor suppressor. Proc Natl Acad Sci U S A. 2009;106(39):16562–7. PubMed PMID: 19805338.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Geddert H, Kiel S, Zotz RB, Zhang J, Willers R, Gabbert HE, et al. Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol. 2005;131(12):803–8. PubMed PMID: 16163549.CrossRefPubMedGoogle Scholar
  35. 35.
    Chen J, Li D, Wei C, Sen S, Killary AM, Amos CI, et al. Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians. Clin Cancer Res. 2007;13(10):3100–4. PubMed PMID: 17505013.PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Qiagen (2006) Purification of total DNA from animal tissues. In: DNeasy blood & tissue handbook, Qiagen, ValenciaGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Ugo Borges Pinheiro
    • 1
  • Carlos Alberto de Carvalho Fraga
    • 1
  • Danilo Cangussu Mendes
    • 1
  • Luciano Marques-Silva
    • 1
  • Lucyana Conceição Farias
    • 1
  • Marcela Gonçalves de Souza
    • 1
  • Mariana Batista Soares
    • 1
  • Kimberly Marie Jones
    • 2
  • Sérgio Henrique Souza Santos
    • 3
  • Alfredo Maurício Batista de Paula
    • 1
  • Gustavo Velásquez-Meléndez
    • 4
  • André Luiz Guimarães
    • 1
  1. 1.Department of DentistryUniversidade Estadual de Montes Claros, Hospital Universitário Clemente de FariaMontes ClarosBrazil
  2. 2.Program in Health SciencesUniversidade Estadual de Montes ClarosMontes ClarosBrazil
  3. 3.Department PharmacologyUniversidade Federal de Minas GeraisBelo HorizonteBrazil
  4. 4.Department of NursingUniversidade Federal de Minas GeraisBelo HorizonteBrazil

Personalised recommendations